Novan Inc

Novan — Investor Presentation (May 2022)

32 slides from Novan's investor presentation, May 20, 2022

  1. Slide 1: Innovative Therapies for Skin Diseases – Corporate Presentation May 2022

    Innovative Therapies for Skin Diseases N A S D A Q : N O V N | n o v a n . c o m C O R P O R AT E P R E S E N TAT I O N / M AY 2 0 2 2 Exhibit 99.1

  2. Slide 2: Forward-Looking Statements

    NOVAN.COM FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements including, but not limited to, statements related to the acquisition of EPI Health, LLC (the “EPI Acquisition”), including the potential benefits of the EPI Acquisition, the therapeutic value and benefits of t

  3. Slide 3: A medical dermatology company for skin diseases

    A medical dermatology company primarily focused on researching, developing and commercializing innovative therapeutic products for skin diseases

  4. Slide 4: Highlights by the Numbers

    NOVAN.COM 4 5 NO-Based Product Candidates in Pipeline (Berdazimer gel, 10.3% (SB206), SB204, SB208, SB414, SB019) 3 Potential Near-Term Value Creators (Berdazimer gel, 10.3% (SB206), Rhofade, Wynzora) 1 NDA Targeted for Submission in 4Q 2022 (Berdazimer gel, 10.3% (SB206)) 4 Promoted Dermatology Pro

  5. Slide 5: A Fully Integrated Medical Dermatology Company

    NOVAN.COM A FULLY INTEGRATED MEDICAL DERMATOLOGY COMPANY 5 ✓ Robust NO-Based Drug Discovery Platform ✓ Proven Clinical-Stage Development Capabilities ✓ In-House cGMP Commercial Manufacturing ✓ Supply Chain and Market Access ✓ Sales and ​Marketing – 42 territories ​ ✓ Financial Management Analytics,

  6. Slide 6: Commercial

    NOVAN.COM Commercial 6

  7. Slide 7: Initially Covering Top 4 Medical Dermatology Markets

    NOVAN.COM 1. Based on the 2003-2006 and 2009-2010 NHANES and U.S. Census Bureau’s Current Population Survey. NHANES=National Health and Nutrition Examination Surveys 2. Rachakonda TD et aJ Am Acad Dermatol 2014;70:512-6.l; 3. IQVIA, NPA, 2019 3. ”Understanding Rosacea.” Rosacea.org, accessed 10 Jan.

  8. Slide 8: Promoted Medical Dermatology Product Portfolio

    NOVAN.COM PROMOTED MEDICAL DERMATOLOGY PRODUCT PORTFOLIO 8 Sales Reps currently covering 42 territories across the U.S. with plan to cover 50 by year end

  9. Slide 9: Growth Performance of Promoted Brands

    NOVAN.COM 2021 TRx’s 10,030 117,436 25,213 44,647 Q1 2022 TRx’s 9,287 37,154 7,342 10,894 Q4’21 vs. Q1’22 Growth 36% 14% 15% -3% Q1’21 vs. Q1’22 Growth N/A 47% 49% -4% GROWTH PERFORMANCE OF PROMOTED BRANDS1 1. Source: IQVIA’s SMART Database – U.S. Edition 9 3,194 6,836 9,287 25,208 30,714 28,931 32,

  10. Slide 10: Commercial Capabilities

    NOVAN.COM COMMERCIAL CAPABILITIES 10 Established Presence Across the Dermatology Community ✓ Supply Chain And Market Access Well established dermatology specialty pharmacy network Comprehensive market access (payor strategy, patient assistance program) Established supply chain with 3rd parties ✓ Sal

  11. Slide 11: Key Growth Mandates to Expand Promoted Products

    NOVAN.COM KEY GROWTH MANDATES TO EXPAND PROMOTED PRODUCTS 11 Expand presence at premier dermatology meetings Increase utilization of omni-channel marketing/sales opportunities Raise awareness among target prescribers Strengthen KOL relationships Explore ex-U.S. opportunities Hire experienced sales l

  12. Slide 12: Research & Development

    NOVAN.COM Research & Development 12

  13. Slide 13: Development Pipeline

    NOVAN.COM DEVELOPMENT PIPELINE 1. Subject to additional funding 2. Programs are not currently in active development 13 Product Candidate Indication Pre-IND Phase 1 Phase 2 Phase 3 Approval Next Targeted Milestone1 PRIORITY DEVELOPMENT PIPELINE SB206 (berdazimer gel, 10.3%) Molluscum NDA Submission 4

  14. Slide 14: Nitricil Platform

    NOVAN.COM NITRICILTM PLATFORM 14 Active Pharmaceutical Ingredient: Berdazimer Sodium New Chemical Entity Patients treated to date: ~4,000 Compelling safety profile IP until as late as 2035

  15. Slide 15: Compelling Total Addressable Markets from Priority Development Pipeline

    NOVAN.COM COMPELLING TOTAL ADDRESSABLE MARKETS FROM PRIORITY DEVELOPMENT PIPELINE 15 Product Candidate SB206 (berdazimer gel, 10.3%) SB204 SB019 Type Topical Gel Topical Gel Nasal Suspension Indication Molluscum Acne COVID-19 Potential Global Addressable Market ~12 Million people1 ~733 Million peopl

  16. Slide 16: SB206 Molluscum Contagiosum

    NOVAN.COM SB206 (berdazimer gel, 10.3%) Molluscum Contagiosum 16 Potential to Be First-In-Class Prescription Treatment for Molluscum

  17. Slide 17: SB206 Berdazimer Gel, 10.3%

    NOVAN.COM SB206 BERDAZIMER GEL, 10.3% 17 1. Molluscum Contagiosum - Epidemiology Forecast – 2028. Seven Major Markets (U.S., Germany, Spain, Italy, France, the United Kingdom, and Japan from 2017 – 2028) 2. Syneos Health Consulting Primary (n=40 Pediatricians, n=39 Dermatologists, n=4 Pediatric Derm

  18. Slide 18: Pivotal B-SIMPLE4 Phase 3: Primary Efficacy Endpoint at Week 12

    NOVAN.COM PIVOTAL B-SIMPLE4 PHASE 3: PRIMARY EFFICACY ENDPOINT AT WEEK 12 18 Percentage of Subjects with Complete Clearance of Treatable Lesions 0.9% 3.6% 11.6% 19.7% 1.4% 7.2% 19.6% 32.4% Week 2 Week 4 Week 8 Week 12 Vehicle SB206 **** ** * p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001

  19. Slide 19: Pivotal Phase 3: Secondary Endpoints

    NOVAN.COM 19 PIVOTAL PHASE 3: SECONDARY ENDPOINTS 90% Clearance and 0 or 1 Remaining Lesions at Week 12 23.90% 24.60% 43% 43.50% 90% Clearance at Week 12 0 or 1 Lesions at Week 12 Vehicle SB206 ************ p-value <0.0001

  20. Slide 20: Pivotal Phase 3: Secondary Endpoint – Change at Week 12

    NOVAN.COM 20 PIVOTAL PHASE 3: SECONDARY ENDPOINT - CHANGE AT WEEK 4 0% -1.31% -5.55% -14.53% -31.28% -12.91% -27.12% -49.25% -57.48% BL Week 2 Week 4 Week 8 Week 12 Vehicle SB206 p-value <0.05 p-value <0.01 p-value <0.001 p-value <0.0001 * ** *** **** *** **** **** **** % Change From Baseline Lesion

  21. Slide 21: NDA Submission Targeted 4Q 2022

    NOVAN.COM NDA SUBMISSION TARGETED 4Q 2022 21 SB206 (berdazimer gel, 10.3%) Aims to be the First FDA-Approved Prescription Treatment for Molluscum  Finalize B-SIMPLE4 Week-24 Readout 3Q 2021 2Q 2022 4Q 2022  Launch Pre- Commercial Activities NDA-Enabling Stability Testing  Pre-NDA Meeting with FDA

  22. Slide 22: Strategic Initiatives for Launch Readiness

    NOVAN.COM 22 STRATEGIC INITIATIVES FOR LAUNCH READINESS Ongoing Activities to Support Successful Potential Launch and Commercialization of Berdazimer Gel, 10.3% (SB206) Scale commercial manufacturing Pricing and reimbursement strategy Medical affairs outreach Sales force training and alignment

  23. Slide 23: Molluscum Therapeutic Landscape

    NOVAN.COM MOLLUSCUM THERAPEUTIC LANDSCAPE 231. Syneos Health Consulting Market Opportunity Assessment for SB206 in Molluscum Contagiosum (2019) ~1.3 million new U.S. cases diagnosed annually1 Potential Therapy Characteristics Topical – SB206 (berdazimer gel, 10.3%) Prescription treatment at home Saf

  24. Slide 24: SB204 Acne Vulgaris

    NOVAN.COM SB204 Acne Vulgaris 24 Late-stage asset with two completed Phase 3 studies

  25. Slide 25: Regulatory Path for SB204 in Acne

    NOVAN.COM REGULATORY PATH FOR SB204 IN ACNE1 25 Next Steps: Two Phase 3 studies completed in 2017 One pivotal Phase 3 study to be conducted Size of trial estimated to include >1,000 patients 3 co-primary endpoints (non-inflammatory lesions, inflammatory lesions, IGA success) Prepare for Pivotal Stud

  26. Slide 26: SB019 COVID-19

    NOVAN.COM 26 SB019 COVID-19 Pre-IND Filed April 2022

  27. Slide 27: Regulatory Path for SB019 in COVID-19

    NOVAN.COM REGULATORY PATH FOR SB019 IN COVID-191 27 Pre-clinical IND enabling studies completed2 Candidate formulation administered intranasally in animals Berdazimer sodium well-tolerated up to the maximum dose tested Drug-device combination in development for potential Phase 2/3 study(s) 1. Subjec

  28. Slide 28: Corporate Overview

    NOVAN.COM Corporate Overview 28

  29. Slide 29: Financial Snapshot

    NOVAN.COM FINANCIAL SNAPSHOT 1. Existing cash runway into early fourth quarter of 2022 based on Management’s projections and planned development and operating activities described in the Company’s March 31, 2022 Form 10-Q as filed with the SEC on May 16, 2022 29 $35.5M Cash as of March 31, 20221 20

  30. Slide 30: Proven Team with Expertise Across Drug Development and Commercialization

    NOVAN.COM 30 PROVEN TEAM WITH EXPERTISE ACROSS DRUG DEVELOPMENT AND COMMERCIALIZATION Paula Brown Stafford, MPH President, Chief Executive Officer and Chairman Tomoko Maeda-Chubachi, MD, Ph.D., MBA Chief Medical Officer Carri Geer, Ph.D. SVP, Chief Technology Officer Brian M. Johnson, MBA Chief Comm

  31. Slide 31: Focus Going Forward

    NOVAN.COM 31 A medical dermatology company primarily focused on researching, developing and commercializing innovative therapeutic products for skin diseases Grow sales and expand commercial organization through multiple initiatives Advance berdazimer gel, 10.3% (SB206) towards NDA, submission targe

  32. Slide 32: Thank You!

    Innovative Therapies for Skin Diseases N A S D A Q : N O V N | n o v a n . c o m Thank You!

Novan — Investor Presentation (May 2022) on 6ix